News Center

News Center

The latest clinical updates and product development news from Progenity.

This acquisition further strengthens Progenity’s existing intellectual property portfolio and development of ingestible devices designed to advance research, diagnosis, and treatment for conditions of the gastrointestinal (GI) tract.

Dr. Kotzin’s experience in the development of novel biotherapeutics, especially in autoimmune and inflammatory diseases, will provide valuable guidance as the company advances its pipeline of precision therapeutics/biotherapeutics and diagnostics.

Announcing a collaborative research and development initiative for women’s health with a focus on preterm births.

Announcing our new Senior Vice President and Chief Financial Officer (CFO).

We announced results from three studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies.

Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, this week announced three upcoming poster presentations.

Highlighting the Resura™ Prenatal Test

Progenity also announces improvements to its Innatal® noninvasive prenatal test (NIPT), demonstrating market-leading sensitivity and specificity across all common chromosomal aneuploidies.

Zoom in from full chromosome to single nucleotide with a new application for cell-free DNA (cfDNA) technology. Expand your patients’ prenatal options with the Resura™ Prenatal Test.